Investors and Partnering 2019-08-29T09:52:24+00:00

Investors and partnering

ADCendo is currently a resident incubation company at Bioinnovation Institute (BII) at the Creation House level, where final proof-of-concept studies, de-risking activities, clinical and regulatory preparation, and selection of a clinical development candidate ADC takes place (2019 and 2020).

ADCendo has previously secured non-dilutive funding through exploratory pre-seed (500,000 DKK) and pre-seed (3,500,000 DKK) grants from Novo Holdings, as well as investments from Innovation Fund Denmark through the InnoBooster and InnoFounder programs.

ADCendo welcomes discussions with investors, VCs, potential partners and pharma companies with an interest in ADCs, to explore potential collaboration opportunities for our continued projects and activities.